

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE
CONVEYING PARTY DATA	
Name	Execution Date
SCRIPPS RESEARCH INSTITUTE	06/24/1993
RECEIVING PARTY DATA	
Name:	National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS), U.S. Government
Street Address:	NIH Division of Extramural Inventions and Technology Resources (DEITR)
Internal Address:	6705 Rockledge Drive, Suite 310, MSC 7980
City:	Bethesda
State/Country:	MARYLAND
Postal Code:	20892-7980
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	07367454
CORRESPONDENCE DATA	
Fax Number:	(301)480-0272
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
Email:	edison@nih.gov
Correspondent Name:	Director, DEITR
Address Line 1:	NIH, 6705 Rockledge Drive, Suite 310
Address Line 2:	MSC 7980
Address Line 4:	Bethesda, MARYLAND 20892-7980
NAME OF SUBMITTER:	Director,DEITR, NIH
Total Attachments: 1 source=07367454mrs#page1.tif	

COPY

LICENSE TO THE UNITED STATES GOVERNMENT

TSRI CASE NO: 78.2

INVENTION TITLE: Acute Phase Protein Modulating Endotoxic Activity of Lipopolysaccharides, Assay Methods and Polypeptides

INVENTORS: Richard Ulevitch, Peter Tobias


PATENT OR APPLICATION SERIAL NUMBER: 07/367,454

U.S. FILING/ISSUE DATE: June 16, 1989

GRANT/CONTRACT IDENTIFICATION NUMBER: AI 15136

The invention identified above is a Subject Invention under 35 U.S.C. Section 200, et seq., and the standard patent rights clause at 37 CFR Section 401.14 or FAR 52.227-11 is included among the terms of the above-identified grant/contract award from the Public Health Service/National Institutes of Health. This document constitutes notice and confirmation of the election of The Scripps Research Institute to retain title to this Subject Invention. This document is confirmatory of:

1. The nonexclusive, nontransferable, irrevocable, paid-up license granted under 35 U.S.C. Section 200 et. seq. to the Federal Government to practice or have practiced for or on behalf of the Federal Government the invention described in the patent application and in any and all divisions, and continuations, and in any and all patents and re-issues granted thereon, and
2. All other rights acquired by the Government by reason of the above-identified grant/contract award and the laws and regulations which are applicable to the award.

By: 

Arnold LaGuardia
Senior Vice President
The Scripps Research Institute

Date: JUN 24 1993